1 Introduction to Research & Analysis Reports 1.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Definition 1.2 Market Segments 1.2.1 Segment by Type 1.2.2 Segment by Application 1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Overview 1.4 Methodology & Sources of Information 1.4.1 Research Methodology 1.4.2 Research Process 1.4.3 Base Year 2 China Benign Prostatic Hyperplasia (BPH) Drugs Overall Market Size 2.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size: 2021 VS 2027 2.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Prospects & Forecasts: 2016-2027 2.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales: 2016-2027 3 Company Landscape 3.1 Top Benign Prostatic Hyperplasia (BPH) Drugs Players in China Market 3.2 Top China Benign Prostatic Hyperplasia (BPH) Drugs Companies Ranked by Revenue 3.3 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Companies 3.4 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Companies 3.5 China Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturer (2016-2021) 3.6 Top 3 and Top 5 Benign Prostatic Hyperplasia (BPH) Drugs Companies in China Market, by Revenue in 2020 3.7 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type 3.8 Tier 1, Tier 2 and Tier 3 Benign Prostatic Hyperplasia (BPH) Drugs Players in China Market 3.8.1 List of Tier 1 Benign Prostatic Hyperplasia (BPH) Drugs Companies in China 3.8.2 List of Tier 2 and Tier 3 Benign Prostatic Hyperplasia (BPH) Drugs Companies in China 4 Sights by Type 4.1 Overview 4.1.1 By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Market Size Markets, 2021 & 2027 4.1.2 Alpha-Blocker 4.1.3 Phosphodiesterase Type-5 Inhibitors 4.1.4 Others 4.2 By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue & Forecasts 4.2.1 By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue, 2016-2021 4.2.2 By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue, 2022-2027 4.2.3 By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share, 2016-2027 4.3 By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Sales & Forecasts 4.3.1 By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Sales, 2016-2021 4.3.2 By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Sales, 2022-2027 4.3.3 By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share, 2016-2027 4.4 By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Price (Manufacturers Selling Prices), 2016-2027 5 Sights by Application 5.1 Overview 5.1.1 By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Market Size, 2021 & 2027 5.1.2 Hospitals 5.1.3 Drugstores 5.1.4 Others 5.2 By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue & Forecasts 5.2.1 By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue, 2016-2021 5.2.2 By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue, 2022-2027 5.2.3 By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share, 2016-2027 5.3 By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Sales & Forecasts 5.3.1 By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Sales, 2016-2021 5.3.2 By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Sales, 2022-2027 5.3.3 By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share, 2016-2027 5.4 By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Price (Manufacturers Selling Prices), 2016-2027 6 Manufacturers & Brands Profiles 6.1 Eli Lilly 6.1.1 Eli Lilly Corporation Information 6.1.2 Eli Lilly Overview 6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.1.5 Eli Lilly Recent Developments 6.2 GlaxoSmithKline 6.2.1 GlaxoSmithKline Corporation Information 6.2.2 GlaxoSmithKline Overview 6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.2.5 GlaxoSmithKline Recent Developments 6.3 Astellas Pharma 6.3.1 Astellas Pharma Corporation Information 6.3.2 Astellas Pharma Overview 6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.3.5 Astellas Pharma Recent Developments 6.4 Sanofi 6.4.1 Sanofi Corporation Information 6.4.2 Sanofi Overview 6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.4.5 Sanofi Recent Developments 6.5 Pfizer 6.5.1 Pfizer Corporation Information 6.5.2 Pfizer Overview 6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.5.5 Pfizer Recent Developments 6.6 Abbott 6.6.1 Abbott Corporation Information 6.6.2 Abbott Overview 6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.6.5 Abbott Recent Developments 6.7 Allergan 6.7.1 Allergan Corporation Information 6.7.2 Allergan Overview 6.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.7.5 Allergan Recent Developments 6.8 TEVA 6.8.1 TEVA Corporation Information 6.8.2 TEVA Overview 6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.8.5 TEVA Recent Developments 6.9 Mylan 6.9.1 Mylan Corporation Information 6.9.2 Mylan Overview 6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.9.5 Mylan Recent Developments 6.10 Novartis 6.10.1 Novartis Corporation Information 6.10.2 Novartis Overview 6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.10.5 Novartis Recent Developments 6.11 Merck 6.11.1 Merck Corporation Information 6.11.2 Merck Overview 6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in China Market (2016-2021) 6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Description 6.11.5 Merck Recent Developments 7 China Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, Analysis 7.1 China Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity, 2016-2027 7.2 Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity of Key Manufacturers in China Market 8 Key Market Trends, Opportunity, Drivers and Restraints 8.1 Market Opportunities & Trends 8.2 Market Drivers 8.3 Market Restraints 9 Benign Prostatic Hyperplasia (BPH) Drugs Supply Chain Analysis 9.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Value Chain 9.2 Benign Prostatic Hyperplasia (BPH) Drugs Upstream Market 9.3 Benign Prostatic Hyperplasia (BPH) Drugs Downstream and Clients 9.4 Marketing Channels Analysis 9.4.1 Marketing Channels 9.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors and Sales Agents in China Market 10 Conclusion 11 Appendix 11.1 Note 11.2 Examples of Clients 11.3 Author Details 11.4 Disclaimer

List of Tables Table 1. Key Players of Benign Prostatic Hyperplasia (BPH) Drugs in China Market Table 2. Top Benign Prostatic Hyperplasia (BPH) Drugs Players in China Market, Ranking by Revenue (2019) Table 3. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Companies, (US$, Mn), 2016-2021 Table 4. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Companies, 2016-2021 Table 5. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Companies, (M Units), 2016-2021 Table 6. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Companies, 2016-2021 Table 7. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Price (2016-2021) & (US$/Unit) Table 8. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type Table 9. List of Tier 1 Benign Prostatic Hyperplasia (BPH) Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share Table 10. List of Tier 2 and Tier 3 Benign Prostatic Hyperplasia (BPH) Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share Table 11. Major Manufacturers of Alpha-Blocker Table 12. Major Manufacturers of Phosphodiesterase Type-5 Inhibitors Table 13. By Type – China Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$, Mn), 2021 & 2027 Table 14. By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$, Mn), 2016-2021 Table 15. By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$, Mn), 2022-2027 Table 16. By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), 2016-2021 Table 17. By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), 2022-2027 Table 18. By Application – China Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$, Mn), 2021 VS 2027 Table 19. By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$, Mn), 2016-2021 Table 20. By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$, Mn), 2022-2027 Table 21. By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), 2016-2021 Table 22. By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), 2022-2027 Table 23. Eli Lilly Corporation Information Table 24. Eli Lilly Description and Major Businesses Table 25. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 26. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Table 27. Eli Lilly Recent Developments Table 28. GlaxoSmithKline Corporation Information Table 29. GlaxoSmithKline Description and Major Businesses Table 30. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 31. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Table 32. GlaxoSmithKline Recent Developments Table 33. Astellas Pharma Corporation Information Table 34. Astellas Pharma Description and Major Businesses Table 35. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 36. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Table 37. Astellas Pharma Recent Developments Table 38. Sanofi Corporation Information Table 39. Sanofi Description and Major Businesses Table 40. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 41. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Table 42. Sanofi Recent Developments Table 43. Pfizer Corporation Information Table 44. Pfizer Description and Major Businesses Table 45. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 46. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Table 47. Pfizer Recent Developments Table 48. Abbott Corporation Information Table 49. Abbott Description and Major Businesses Table 50. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 51. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Table 52. Abbott Recent Developments Table 53. Allergan Corporation Information Table 54. Allergan Description and Major Businesses Table 55. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 56. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Table 57. Allergan Recent Developments Table 58. TEVA Corporation Information Table 59. TEVA Description and Major Businesses Table 60. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 61. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Table 62. TEVA Recent Developments Table 63. Mylan Corporation Information Table 64. Mylan Description and Major Businesses Table 65. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 66. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Table 67. Mylan Recent Developments Table 68. Novartis Corporation Information Table 69. Novartis Description and Major Businesses Table 70. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 71. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Table 72. Novartis Recent Developments Table 73. Merck Corporation Information Table 74. Merck Description and Major Businesses Table 75. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 76. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Table 77. Merck Recent Developments Table 78. Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity (M Units) of Key Manufacturers in China Market, 2019-2021 (M Units) Table 79. China Benign Prostatic Hyperplasia (BPH) Drugs Capacity Market Share of Key Manufacturers, 2019-2021 Table 80. Benign Prostatic Hyperplasia (BPH) Drugs Market Opportunities & Trends in China Market Table 81. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers in China Market Table 82. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints in China Market Table 83. Benign Prostatic Hyperplasia (BPH) Drugs Raw Materials Table 84. Benign Prostatic Hyperplasia (BPH) Drugs Raw Materials Suppliers in China Market Table 85. Typical Benign Prostatic Hyperplasia (BPH) Drugs Downstream Table 86. Benign Prostatic Hyperplasia (BPH) Drugs Downstream Clients in China Market Table 87. Benign Prostatic Hyperplasia (BPH) Drugs Distributors and Sales Agents in China Market List of Figures Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture Figure 2. Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type Figure 3. Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application Figure 4. China Benign Prostatic Hyperplasia (BPH) Drugs Market Overview: 2020 Figure 5. China Benign Prostatic Hyperplasia (BPH) Drugs Market Size: 2021 VS 2027 (US$, Mn) Figure 6. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue, 2016-2027 (US$, Mn) Figure 7. Benign Prostatic Hyperplasia (BPH) Drugs Sales in China Market: 2016-2027 (M Units) Figure 8. The Top 3 and 5 Players Market Share by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2020 Figure 9. Alpha-Blocker Product Picture Figure 10. Phosphodiesterase Type-5 Inhibitors Product Picture Figure 11. Others Product Picture Figure 12. By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share, 2016-2027 Figure 13. By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share, 2016-2027 Figure 14. By Type - China Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit), 2016-2027 Figure 15. Hospitals Figure 16. Drugstores Figure 17. Others Figure 18. By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share, 2016-2027 Figure 19. By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share, 2016-2027 Figure 20. By Application - China Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit), 2016-2027 Figure 21. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 22. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 23. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 24. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 25. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 26. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 27. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 28. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 29. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 30. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 31. Merck Benign Prostatic Hyperplasia (BPH) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 32. China Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity (M Units), 2016-2027 Figure 33. Benign Prostatic Hyperplasia (BPH) Drugs Industry Value Chain Figure 34. Marketing Channels

Eli Lilly GlaxoSmithKline Astellas Pharma Sanofi Pfizer Abbott Allergan TEVA Mylan Novartis Merck